{"product_id":"global-embolotherapy-market-size-study-forecast-by-product-embolic-agents-support-devices-by-procedure-transcatheter-arterial-embolization-tae-selective-internal-radiation-therapy-sirt-trans-arterial-chemoembolization-tace-by-disease-indi","title":"Global Embolotherapy Market Size study \u0026 Forecast, by Product (Embolic Agents, Support Devices) by Procedure (Transcatheter Arterial Embolization (TAE), Selective Internal Radiation Therapy (SIRT), Trans arterial Chemoembolization (TACE)), by Disease indi","description":"\u003cp\u003eGlobal Embolotherapy Market Size study \u0026amp; Forecast, by Product (Embolic Agents, Support Devices) by Procedure (Transcatheter Arterial Embolization (TAE), Selective Internal Radiation Therapy (SIRT), Trans arterial Chemoembolization (TACE)), by Disease indication (Cancer, Peripheral Vascular Disease, Neurological Diseases, Urological, Nephrological Disorders, Gastrointestinal Disorders), by End user (Hospitals, Clinics, Ambulatory Surgery Centers, Others) and Regional Analysis, 2022-2029\u003cbr\u003e\nGlobal Embolotherapy Market is valued approximately at USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. Embolotherapy is a minimally invasive medical procedure that involves the use of embolic agents to block blood vessels or blood flow in order to treat a variety of medical conditions. Embolic agents can be solid particles, gels, or liquids that are injected directly into a blood vessel, causing the vessel to clot and preventing blood from flowing to a specific area of the body. Embolotherapy is used to treat a variety of conditions, including uterine fibroids, liver tumors, aneurysms, and vascular malformations. The technique is minimally invasive than traditional surgery and can be performed on an outpatient basis in some cases, with shorter recovery times and fewer complications. The key factor driving the market growth is rising demand for the minimally invasive surgical procedures, favorable reimbursement scenario for minimally invasive surgeries and growing technological advancement in embolotherapy devices.\u003c\/p\u003e\n\n\u003cp\u003eThe rising demand for minimally invasive surgical procedures is anticipated to support the growth of the embolotherapy market. Embolotherapy is a minimally invasive technique used to treat a wide range of medical conditions, including cancer, uterine fibroids, aneurysms, and vascular malformations. According to Statista, in 2019, the minimally invasive surgery market globally was valued USD 20.5 billion and it is anticipated to reach USD 44.04 billion by 2030. As a result, the rising demand for the minimally invasive surgical procedures is anticipated to propel the market growth. Additionally, the growing target patient population and rising funding \u0026amp; investment by government and private organizations for the medical and health care facility development is anticipated to create the lucrative opportunity for the market during projected period. However, the lack of sufficient evidence \u0026amp; unfavorable regulatory scenario, and strong market positioning of alternative therapies stifles market growth throughout the forecast period of 2022-2029.\u003c\/p\u003e\n\n\u003cp\u003eThe key regions considered for the Global Embolotherapy Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominates the market holding the largest market share, owing to the presence of key market players, favorable reimbursement policies, and growing investments for the healthcare facility development. Whereas, Asia Pacific is anticipated to exhibit fastest growing region during forecasted period over the forecast period, owing to factors such as booming medical tourism, developing healthcare network and increasing research and development activities in the region would create lucrative growth prospects for the Embolotherapy market across Asia Pacific region.\u003c\/p\u003e\n\n\u003cp\u003eMajor market player included in this report are:\u003cbr\u003e\nImbiotechnologies Ltd.\u003cbr\u003e\nJohnson \u0026amp; Johnson\u003cbr\u003e\nKaneka Corporation\u003cbr\u003e\nMedtronic Plc\u003cbr\u003e\nMeril Life Sciences Pvt. Ltd.\u003cbr\u003e\nMerit Medical Systems, Inc.\u003cbr\u003e\nPenumbra, Inc.\u003cbr\u003e\nSimbionix USA Corporation\u003cbr\u003e\nSirtex Medical Limited\u003cbr\u003e\nStryker Corporation\u003cbr\u003e\nRecent Developments in the Market:\u003cbr\u003e\nIn 2021, Terumo Corporation has received FDA approval for the PMA Supplement for the WEB 17 System, a novel component of the WEB Aneurysm Embolisation System for the treatment of intracranial wide-neck bifurcation aneurysms.\u003c\/p\u003e\n\n\u003cp\u003eGlobal Embolotherapy Market Report Scope:\u003cbr\u003e\nHistorical Data 2019-2020-2021\u003cbr\u003e\nBase Year for Estimation 2021\u003cbr\u003e\nForecast period 2022-2029\u003cbr\u003e\nReport Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends\u003cbr\u003e\nSegments Covered Product, Procedure, Disease indication, End user, Region\u003cbr\u003e\nRegional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World\u003c\/p\u003e\n\n\u003cp\u003eThe objective of the study is to define market sizes of different segments \u0026amp; countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.\u003c\/p\u003e\n\n\u003cp\u003eThe report also caters detailed information about the crucial aspects such as driving factors \u0026amp; challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.\u003c\/p\u003e\n\n\u003cp\u003eThe detailed segments and sub-segment of the market are explained below:\u003c\/p\u003e\n\n\u003cp\u003eBy Product:\u003cbr\u003e\nEmbolic Agents\u003cbr\u003e\nSupport Devices\u003cbr\u003e\nBy Procedure:\u003cbr\u003e\nTranscatheter Arterial Embolization (TAE)\u003cbr\u003e\nSelective Internal Radiation Therapy (SIRT)\u003cbr\u003e\nTrans arterial Chemoembolization (TACE)\u003cbr\u003e\nBy Disease indication:\u003cbr\u003e\nCancer\u003cbr\u003e\nPeripheral Vascular Disease\u003cbr\u003e\nNeurological Diseases\u003cbr\u003e\nUrological\u003cbr\u003e\nNephrological Disorders\u003cbr\u003e\nGastrointestinal Disorders\u003cbr\u003e\nBy End user:\u003cbr\u003e\nHospitals\u003cbr\u003e\nClinics\u003cbr\u003e\nAmbulatory Surgery Centers\u003cbr\u003e\nOthers\u003cbr\u003e\nBy Region:\u003cbr\u003e\nNorth America\u003cbr\u003e\nU.S.\u003cbr\u003e\nCanada\u003cbr\u003e\nEurope\u003cbr\u003e\nUK\u003cbr\u003e\nGermany\u003cbr\u003e\nFrance\u003cbr\u003e\nSpain\u003cbr\u003e\nItaly\u003cbr\u003e\nROE\u003cbr\u003e\nAsia Pacific\u003cbr\u003e\nChina\u003cbr\u003e\nIndia\u003cbr\u003e\nJapan\u003cbr\u003e\nAustralia\u003cbr\u003e\nSouth Korea\u003cbr\u003e\nRoAPAC\u003cbr\u003e\nLatin America\u003cbr\u003e\nBrazil\u003cbr\u003e\nMexico\u003cbr\u003e\nRoLA\u003cbr\u003e\nRest of the World\u003c\/p\u003e\n\n\u003cp\u003eCompanies Mentioned\u003c\/p\u003e\n\n\u003cp\u003eImbiotechnologies Ltd.\u003cbr\u003e\nJohnson \u0026amp; Johnson\u003cbr\u003e\nKaneka Corporation\u003cbr\u003e\nMedtronic Plc\u003cbr\u003e\nMeril Life Sciences Pvt. Ltd.\u003cbr\u003e\nMerit Medical Systems, Inc.\u003cbr\u003e\nPenumbra, Inc.\u003cbr\u003e\nSimbionix USA Corporation\u003cbr\u003e\nSirtex Medical Limited\u003cbr\u003e\nStryker Corporation\u003c\/p\u003e\n\n\u003cp\u003ePlease note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"May, 2023 \/ 200 Pages \/ MCW16241351","offer_id":47657850372402,"sku":null,"price":5940.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/global-embolotherapy-market-size-study-forecast-by-product-embolic-agents-support-devices-by-procedure-transcatheter-arterial-embolization-tae-selective-internal-radiation-therapy-sirt-trans-arterial-chemoembolization-tace-by-disease-indi","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}